You are here

  • Home
  • Archive
  • Volume 5, Issue 10
  • Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 c…

Citation Tools

Article menu

Download PDFPDF

XML
Infectious diseases
Protocol
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Green CA, Scarselli E, Voysey M, et al
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults
BMJ Open 2015;5:e008748. doi: 10.1136/bmjopen-2015-008748